The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects

Overview

This is an open-label, 2-cycle, multiple-dose, single-sequence study in women of child-bearing potential. The primary objective is to assess the effect of BMS-986142 on the pharmacokinetics (PK) of Combined Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone Acetate.

Full Title of Study: “The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone Acetate in Healthy Female Subjects”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2016

Interventions

  • Drug: OC containing EE and NET
  • Drug: BMS-986142

Arms, Groups and Cohorts

  • Experimental: Daily single dose of OC containing EE and NET
    • Daily single dose of OC Containing EE and NET alone.
  • Experimental: Daily single dose of OC in combination with BMS-986142
    • Daily single dose of OC containing EE and NET in combination with BMS-986142.

Clinical Trial Outcome Measures

Primary Measures

  • Maximum observed plasma concentration (Cmax) of EE and NET
    • Time Frame: Cycle 1 Day 21 to Cycle 2 Day 22 (30 days)
  • Area under the concentration-time curve (AUC) of EE and NET
    • Time Frame: Cycle 1 Day 21 to Cycle 2 Day 22 (30 days)
  • Area under the concentration-time curve over the dosing interval [AUC (TAU)] of EE and NET
    • Time Frame: Cycle 1 Day 21 to Cycle 2 Day 22 (30 days)

Secondary Measures

  • Safety endpoints include the incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, and death.
    • Time Frame: Cycle 1 Day 1 to Cycle 2 Day 25; For SAEs up to 30 days post discontinuation of dosing or participation.

Participating in This Clinical Trial

Inclusion Criteria

  • Signed Informed Consent – Target population: Healthy females with no clinically significant deviations from normal in medical history, physical examinations, vital signs, electrocardiograms (ECGs), physical measurements, and clinical laboratory tests that are willing to switch to Loestrin during the study. – Body Mass Index (BMI) between 18 to 32 kg/m2. – Women of childbearing potential with intact ovarian function and history of regular menstrual cycles must have been on a stable regimen of combination of birth control containing ethinyl estradiol without evidence of clinically significant breakthrough bleeding or spotting for at least 2 consecutive months prior to Day -1. – Women of childbearing potential must agree to follow instructions for method(s) of contraception for the duration of treatment with study drugs (53 days) plus 5 half-lives of BMS-986142 (3 days) plus 30 days (duration of ovulatory cycle) for a total of 86 days. Exclusion Criteria:
  • History of any chronic or acute illness including active TB in the last 3 years, recent infection, gastrointestinal disease, smoking within less than 6 months prior to dosing, alcohol abuse, inability to tolerate oral medication, or inability to be venipunctured. – History of jaundice or irregular bleeding associated with taking oral contraceptives, frequent headaches, cerebrovascular or coronary-artery disease, retinal vascular lesions, cancer of the breast or endometrium, deep venous thrombosis, pulmonary embolism, stroke, transient ischemic attack, or phlebitis. – Vaccination or plans for vaccination with any live vaccine 12 weeks prior to first dose of study drug, during the course of the study, or 30 days after the last dose of study drug. – Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, electrocardiograms, or clinical laboratory determinations beyond what is consistent with the target population. – History of allergies and adverse drug reaction to any oral contraceptive compounds or Bruton tyrosine kinase (BTK) inhibitors.
  • Gender Eligibility: Female

    Minimum Age: 18 Years

    Maximum Age: 40 Years

    Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

    Investigator Details

    • Lead Sponsor
      • Bristol-Myers Squibb
    • Provider of Information About this Clinical Study
      • Sponsor
    • Overall Official(s)
      • Bristol-Myers Squibb, Study Director, Bristol-Myers Squibb

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.